This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TCP1 · Western blot design guide
TCP1 Western Blot Planning Guide
Plan a TCP1 Western blot around the catalog-observed 60.3 kDa band, image-backed M02389 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
TCP1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 60.3 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Testis | |
| Negative control | Soft tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 60.3 kDa |
| ⓘ | Localization | Cytoplasm, cytosol / Cytoplasm, cytoskeleton, microtubule organizing center, centrosome |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated TCP1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Gallbladder |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | M02389 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected TCP1 Western Blot Band Size?
Use the product-observed 60.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 60.3 kDa | Matches the authoritative product WB observation. |
| 60.3 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected TCP1 appearancePlan around 60.3 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 60.3 kDa; use this as the primary experimental expectation. |
| Calculated mass | 60.3 kDa from UniProt P17987; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with M02389. |
| Situation | Likely cause | Next action |
|---|---|---|
| 60.3 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing TCP1 band
M02389 · TCP1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for TCP1 Western blot
🧪Use Testis as the first positive-control candidate and Soft tissue as the HPA Not detected negative candidate.
Positive control: Testis (High)
Negative control: Soft tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for TCP1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Testis | Reported tissue cells | High | Protein (HPA) | HPA → |
| Ovary | Reported tissue cells | High | Protein (HPA) | HPA → |
| Gallbladder | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Soft tissue | Reported tissue cells | Not detected | Protein (HPA) | HPA → |
Section 3
Advanced TCP1 Western Blot Tips
Deeper troubleshooting and optimisation questions for TCP1, answered from its protein features.
Which band should guide the blot?
Use 60.3 kDa, the observation attached to the authoritative M02389 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 60.3 kDa expectation.
Which positive control should I start with?
Start with Testis, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Soft tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for TCP1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should M02389 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
TCP1 Western Blot Reagents
Human/Mouse/Rat-reactive TCP1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-TCP1 alpha Antibody Picoband® (monoclonal, 2E7)
Cat # M02389
Real WB data
Anti-TCP1 alpha Antibody Picoband®
Cat # PB9826
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P17987
- Human Protein Atlas — TCP1
- M02389 product record
- PMC8223286 — TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells (Journal of ovarian research, 2021)
- PMC12114683 — The Molecular Chaperone TCP1 Affects Carcinogenicity and Is a Potential Therapeutic Target for Acute Myeloid Leukemia (Pharmaceutics, 2025)
- PMC11341815 — TCP1 expression alters the ferroptosis sensitivity of diffuse large B-cell lymphoma subtypes by stabilising ACSL4 and influences patient prognosis (Cell death & disease, 2024)
